AMG 193 / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AMG 193 / Amgen
NCT06593522: A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC

Recruiting
2
200
Canada, US, RoW
AMG 193
Amgen
MTAP-deleted NSCLC
02/27
02/29
NCT05975073: A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Recruiting
1/2
184
Europe, Canada, US, RoW
AMG 193, IDE397
Amgen
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
08/25
02/27
MTAP, NCT05094336: A Study of AMG 193 in Subjects With Advanced -null Solid Tumors

Recruiting
1/2
649
Europe, Canada, Japan, US, RoW
AMG 193, MTA Cooperative PRMT5 inhibitor, Docetaxel, Comparator AMG 193 Test Tablet
Amgen
Advanced MTAP-null Solid Tumors
04/26
10/27
NCT06360354: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Recruiting
1
188
Europe, Canada, Japan, US, RoW
AMG 193, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX
Amgen
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
02/27
02/29
NCT06333951: AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Recruiting
1
500
Japan, US, RoW
AMG 193, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Amgen
Thoracic Tumors, Non-small Cell Lung Cancer
10/28
10/31

Download Options